Maravai LifeSciences Holdings, Inc.
a life sciences company
MRVI Nasdaq
ISIN US56600D1072 SEC CIK 1823239
Follow Maravai LifeSciences
Weekly email: filings, results
Revenue, last quarter
$45.9M
+10.1% vs same quarter last year
Net income
−$13.8M
+45.8% vs same quarter last year
EPS, diluted
−$0.09
+50% vs same quarter last year
Operating cash flow
$5M
+133.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $185.7M | −$130.8M |
| FY24 | $259.2M | −$144.8M |
| FY23 | $288.9M | −$138.4M |
| FY22 | $883M | $490.7M |
| FY21 | $799.2M | $469.3M |
| FY20 | $284.1M | $89M |
| FY19 | $143.1M | −$4.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 18.3% | −115.9% | −70.4% |
| FY24 | 41.8% | −90.9% | −55.9% |
| FY23 | 48.5% | −11% | −47.9% |
| FY22 | 80.9% | 65% | 55.6% |
| FY21 | 82.4% | 69.4% | 58.7% |
| FY20 | 72% | 42.2% | 31.3% |
| FY19 | 53.3% | 16.8% | −3.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$70.7M |
| FY24 | −$22.2M |
| FY23 | $60.7M |
| FY22 | $518.9M |
| FY21 | $353.7M |
| FY20 | $126.8M |
| FY19 | $7M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $33.7M |
| FY19 | $0 |
- Maravai LifeSciences
- Healthcare median
Show the numbers
| Year | Maravai LifeSciences | Healthcare median |
|---|---|---|
| FY25 | −70.4% | −30.6% |
| FY24 | −55.9% | −47% |
| FY23 | −47.9% | −58% |
| FY22 | 55.6% | −80.4% |
| FY21 | 58.7% | −71.8% |
| FY20 | 31.3% | −62.2% |
| FY19 | −3.1% | −46.2% |